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Abstract
Background—After endoscopic radiofrequency ablation (RFA) of dysplastic Barrett's
esophagus (BE), endoscopic biopsy samples are obtained to assess response to therapy. Whether
these biopsies are of adequate depth to assess efficacy is unknown.
Objective—To compare the depth of endoscopic biopsy samples after RFA with those of
untreated controls and to determine the prevalence of subepithelial structures in endoscopic biopsy
fragments.
Design—Secondary analysis of the AIM Dysplasia Trial, a multicenter, randomized, sham-
controlled study.
Setting—Nineteen treatment centers.
Patients—Subjects with dysplastic BE, either status post RFA or ablation naïve (sham).
Main Outcome Measurements—The proportion of biopsy samples demonstrating
subepithelial structures, stratified by tissue type (columnar vs squamous) in sham- and RFA-
treated subjects.
Results—A total of 5648 biopsy fragments were analyzed from 113 subjects (78 RFA, 35 sham;
mean 50.0 fragments per subject). Most fragments (4653, 82.4%) contained subepithelium.
Squamous biopsy samples from RFA and sham subjects demonstrated subepithelium at similar
rates (78.4% vs 79.1%, respectively, P = not significant [NS]). Columnar biopsy samples from
RFA and sham subjects also included subepithelium at similar rates (99.0% vs 98.8%,
respectively, P = NS). Regardless of treatment assignment, more columnar than squamous biopsy
samples demonstrated subepithelium (98.8% vs 78.5%, P < .001).
Limitations—Biopsy samples were not individually mounted.
Conclusions—In both squamous and columnar tissue, endoscopic biopsy samples after RFA
were as likely to demonstrate subepithelium as untreated controls. Almost 80% of all biopsy
samples were adequate to evaluate for subsquamous intestinal metaplasia. The primary
determinant of biopsy depth is the type of epithelium that underwent biopsy, with squamous less
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likely to yield subepithelium than columnar. Biopsy samples after RFA appear to be of adequate
depth to assess response to therapy.
Barrett's esophagus (BE) is characterized by intestinal metaplasia (IM) of the esophagus, a
premalignant change in the esophagus from squamous to specialized columnar epithelium.1
Because of the risk of progression to esophageal adenocarcinoma, endoscopic techniques
have been developed to ablate BE with the goal of decreasing the progression to
malignancy. Radiofrequency ablation (RFA) is an endoscopic ablation technique involving
the application of a bipolar electrical array to deliver a standardized thermal injury. This
injury, followed by aggressive acid suppressive therapy, results in the regeneration of a
histologically normal-appearing neosquamous epithelium in most subjects.2,3 Successful
eradication of BE appears to be associated with a decreased risk of cancer.4,5
Endoscopic surveillance with biopsies is commonly performed after endoscopic ablation.
Endoscopic biopsy samples are obtained from the neosquamous epithelium to confirm
treatment response and to assess for subsquamous intestinal metaplasia (SSIM)–residual
intestinal metaplasia that is buried beneath the neosquamous epithelium. The ability to
accurately assess for a complete response depends on the quality and depth of surveillance
biopsies. Biopsy to at least the depth of the lamina propria (LP) is required to assess for
SSIM.6
It is unclear whether surveillance biopsy samples adequately assess the subsquamous space.
If mucosal scarring or other changes inhibit biopsy depth, current endoscopic surveillance
practices may not detect SSIM. Previous studies did not establish whether most endoscopic
biopsy samples after ablation therapy are from an adequate depth to include subepithelial
structures and/or detect SSIM. To address this question, we performed a secondary analysis
of the AIM Dysplasia Trial.4 The objectives of this study were (1) to compare the depth of
endoscopic biopsy in subjects who underwent RFA of dysplastic BE with concurrently
enrolled, untreated controls and (2) to determine the prevalence of subepithelial structures in




The AIM Dysplasia Trial (see online Appendix for complete list of investigators; available
at www.giejournal.org) is a multicenter, randomized, sham-controlled study in which
patients with dysplastic BE (low-grade dysplasia [LGD] or high-grade dysplasia [HGD])
were randomized to receive RFA therapy plus endoscopic surveillance or a sham
intervention plus surveillance. A detailed description of the study methods was reported
elsewhere, but is briefly described here.4 Patients were eligible if they were ages 18 to 80
and had 8 cm or less of non-nodular dysplastic BE. Subjects were randomly assigned in a
2:1 ratio to receive either RFA or a sham endoscopic procedure. In the ablation group, the
BE segment was ablated with RFA (HALO360 and HALO90; BÂRRX Medical, Sunnyvale,
Calif). Each subject received esomeprazole 40 mg twice daily throughout the study. All
subjects underwent endoscopic surveillance at 3-month (HGD cohort) or 6-month (LGD
cohort) intervals. Biopsy samples were obtained at each endoscopy with jumbo or maximum
capacity forceps in 4 quadrants every 1 cm from the baseline extent of BE and from areas of
mucosal atypia. The primary outcomes at 12 months were complete eradication of dysplasia
and metaplasia, reported separately.4
Take-home Message
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• In both squamous and columnar tissue, endoscopic biopsy samples from patients
treated with radiofrequency ablation were as likely to demonstrate
subepithelium as untreated controls. The primary determinant of biopsy depth is
the type of epithelium that underwent biopsy, with squamous tissue less likely
than columnar tissue to yield subepithelial structures. Biopsy samples after RFA
appear to be of adequate depth to assess the response to therapy.
The study protocol was approved by each site's institutional review board. The parent study
was supported by BÂRRX Medical, maker of the ablation devices, with study medication
provided by AstraZeneca.
Histological analysis
Our analysis used biopsy specimens obtained at 1 year after randomization, the primary
endpoint. Biopsy specimens of subjects who were found to have esophageal
adenocarcinoma in the first year of follow-up and who underwent nonendoscopic treatment
were excluded. Tissue was fixed in formalin and stained with hematoxylin and eosin.
Fragments from each 1-cm segment were collected in a separate jar. Each individual
fragment was interpreted by a single expert GI pathologist (J.R.G.) at a central laboratory
(Cleveland Clinic) for its tissue type and depth.
Each fragment was classified as (1) squamous only, (2) glandular only (no IM), (3)
glandular (no IM) plus squamous (mixed fragment), and (4) any IM present.
For the purpose of our analysis, columnar biopsy samples included fragments classified as
glandular only, glandular plus squamous, or IM.
The maximum histological depth of each fragment was characterized as follows: partial
epithelium (Fig. 1A), full epithelium (basement membrane present [Fig. 1B]), LP (Fig. 1C),
muscularis mucosae (Fig. 1D), and submucosa (Fig. 1E). A biopsy fragment that included
LP papillae was categorized as LP (Fig. 1F). A subepithelial biopsy sample was considered
any fragment that included LP, muscularis mucosae, or submucosa. Biopsy samples were
considered adequate for evaluation of SSIM if they contained any subepithelial structures.
Statistical analysis
Means and standard deviations are reported for continuous variables. Proportions are
reported for categorical data. To compare participant's characteristics and biopsy depth
results, the Pearson χ2 test or the Fisher exact test was used, as appropriate. To account for
correlation because of multiple biopsy samples from the same patient, generalized
estimating equations were used. All tests of significance were 2 tailed with α values <.05
significant. All analyses were performed with SAS software, version 9.0 (SAS Institute,
Cary, NC).
RESULTS
In the parent study, 755 patients were screened for participation and 127 patients were
randomized (Fig. 2). Of those randomized, 117 subjects underwent the 12-month endoscopy.
By the 12-month endoscopy, the disease progressed to esophageal adenocarcinoma in 4
subjects in the sham group and 1 subject in the RFA group. The RFA subject was treated
with endoscopic mucosal resection for cancer, and although failing this endpoint, did
provide 12-month biopsy samples for this analysis. Therefore, the biopsy results from a total
of 113 subjects (78 RFA, 35 sham) were included in this study. Their demographic and
disease-specific characteristics are listed in Table 1. The characteristics of the subjects in the
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2 groups differ significantly only with respect to an elevated body mass index in the sham
group.
A total of 5648 biopsy fragments were available at the 12-month endpoint (78 RFA, 35
sham; mean 50.0 fragments per patient). Of these, 4653 (82.4%) contained subepithelial
structures. Considering the RFA and sham groups separately, a greater proportion of sham
biopsy samples contained subepithelium (88.9% vs 80.0%, P < .0001). However, the
difference in subepithelial yield of biopsy samples between RFA and sham groups was
entirely explained by the tissue type that underwent biopsy. Regardless of randomization
group, a lower proportion of squamous-only than columnar biopsy samples demonstrated
subepithelial structures (78.5% vs 98.8%, respectively; P > .001). Because RFA biopsy
samples were more likely to contain squamous epithelium than were sham biopsy samples,
9% fewer biopsy samples in the RFA group contained subepithelial structures. These results
were unchanged and remained statistically significant after accounting for intrapatient
correlation.
Biopsy samples containing squamous-only mucosa obtained from RFA versus sham subjects
included subepithelial structures at similar rates (78.4% vs 79.1%, respectively; P = not
significant [NS]), whereas biopsy samples containing columnar mucosa obtained from RFA
versus sham subjects also included subepithelial structures at similar rates (99.0% vs 98.8%,
respectively; P = NS) (Table 2). Biopsies of columnar tissue from sham patients did obtain
more fragments with the deepest layer, submucosa, than those from RFA patients (8.4 vs
3.0%, respectively). However, this difference was explained by a higher proportion of mixed
fragments (fragments containing both glandular and squamous tissue) among the columnar
tissue fragments in the sham group compared with the RFA group (7.1% vs 1.2%, P = .07).
Mixed fragments were less likely to display submucosa, so fewer columnar biopsy samples
from RFA patients demonstrated submucosa. When mixed fragments were not included in
the analysis, no difference was noted in yield of submucosa in glandular or IM fragments
from the RFA and sham groups. Overall, after stratifying for tissue type, there was no
difference in the proportion of biopsy samples demonstrating subepithelial structures
between the RFA and sham groups.
DISCUSSION
Complete eradication of BE requires confirming the absence of both surface and
subsquamous IM. The clinical relevance of subsquamous IM is unclear, but may represent a
predisposing lesion to the development of subsquamous adenocarcinoma. Studies of RFA in
BE, including the parent study of this analysis, have demonstrated a high rate of complete
eradication of BE and a low prevalence of SSIM.4,7-9 In this randomized trial, the rate of
SSIM decreased from 25% to 5.1% in the group undergoing RFA therapy. In all of these
cases of SSIM, the residual IM was found at the level of the LP. Although the current
literature suggests a high rate of complete eradication by using RFA, there is concern that it
may be more difficult to perform a biopsy on neosquamous epithelium, and therefore SSIM
may be masked.
Our data suggest that the majority of biopsy samples obtained from subjects regardless of
RFA versus sham designation contained subepithelium and were of adequate depth to be
informative for SSIM. However, individual biopsy fragments from subjects after RFA were
less likely to contain subepithelial structures than biopsy samples from the sham group (80%
vs 89%, respectively). We initially postulated that this difference might be related to
scarring or fibrosis of the mucosa after RFA, but instead found the difference to be related to
the tissue type undergoing biopsy. Regardless of treatment group, squamous-only biopsy
samples were less likely to contain subepithelial structures than columnar biopsy samples
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(79% vs 99%, respectively). Because the RFA group had a much higher proportion of
squamous-only biopsy samples than the sham group (as would be expected because the large
majority underwent successful RFA with subsequent complete neosquamous regeneration),
this difference in predominant tissue type accounted for the 9% overall difference (80% vs
89%) in subepithelium per fragment between the groups. These results are reassuring and
lend credibility to the studies that have shown a low prevalence of SSIM in patients treated
with RFA.
To date, 2 groups have examined biopsy depth after endoscopic ablation. Pouw et al3
published an analysis of biopsy fragments from 16 subjects with BE (HGD or early cancer)
status post RFA. Biopsy samples taken from the postablation neosquamous epithelium (194
biopsy fragments) were compared with untreated proximal squamous epithelium (60 biopsy
fragments). Subjects were randomized to standard or jumbo biopsy forceps. They reported
no difference in subepithelial yield of biopsy samples when comparing postablation
neosquamous epithelium (37% to the LP) with untreated squamous epithelium (36% to the
LP). They also reported no difference in biopsy depth between samples obtained by using
standard or jumbo biopsy forceps.
Overholt et al10 also studied biopsy depth after endoscopic ablation. They analyzed biopsy
depth in BE subjects status post either endoscopic RFA or photodynamic therapy compared
with ablation-naïve subjects with BE, reflux, or dyspepsia. Endoscopic biopsy samples were
taken with jumbo or maximum-capacity forceps from the neosquamous epithelium in
participants with BE status post RFA (n = 60), in those with BE status post photodynamic
therapy (n = 12), and in ablation-naïve subjects (n = 23). They found that 91% of the biopsy
samples in subjects after RFA, 88% of the biopsy samples in subjects after photodynamic
therapy, and 90% of biopsy samples in subjects who were ablation naïve contained
subepithelium (P = NS). The prevalence of subepithelial structures in the regenerated
squamous tissue in this study was much higher than that reported by Pouw et al3 (91% vs
37%, respectively) and closer to our estimate of 78%.
Although both the current study and the study by Pouw et al demonstrated no difference in
subepithelial yield in treated and untreated tissue (stratified by tissue type), the proportion of
subepithelial structures in squamous tissue differs remarkably (37% vs 78% in the current
study). The etiology of this difference is unclear; however, several possible explanations
exist.
First, the observed difference could be secondary to differences in histological
interpretation. Biopsy specimens were reviewed in the Pouw et al study by 3 expert GI
pathologists; in comparison, our specimens were reviewed by 1 expert GI pathologist. By
definition, our study required the presence of any element of LP (including papillae) be
present to consider the biopsy of sufficient depth to detect SSIM. We adopted this definition
for 2 reasons: first, any other convention attempting to mandate a certain amount,
proportion, or orientation of LP is arbitrary and would introduce further subjectivity, and,
second, in our study, we found no incidence when LP papillae projected upward through a
sheet of SSIM. If conventions for assessing the presence of LP were different, this could
account for the difference in proportions of the presence of LP between studies. However,
this reason seems less likely because Pouw et al also considered LP to be present if any LP,
including LP papillae, was present (personal communication between NJ Shaheen and RE
Pouw, December 17, 2009).
It is also possible that after ablation, neosquamous epithelium becomes thicker over time as
it regenerates. The Pouw et al study biopsy samples were obtained a median of 26 months
after the lst RFA treatment. In comparison, our study biopsy samples were obtained at 12
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months after study enrollment and as soon as 3 months after the last RFA treatment. If
neosquamous epithelium thickens over time, it might account for the higher subepithelial
yield in our population; it would be easier to retrieve subepithelium in biopsy samples
through the thinner epithelial layer of a patient who recently underwent ablation. However,
if this were true, we would have expected to see a higher subepithelial yield in the squamous
biopsy samples from RFA-treated patients, not the sham patients, because sham squamous
epithelium underwent no regeneration. Instead, we found that biopsy samples from
squamous mucosa obtained from RFA patients and sham patients included subepithelial
structures at almost identical rates (78.4% vs 79.1%, respectively, P = NS).
Also of note, more than half of the subjects in the Pouw et al study had a history of EMR
before RFA treatment. In comparison, 8 (9%) of the treatment patients in our study
underwent limited EMR before randomization. Characteristics of post-EMR tissue might be
different from those of tissue subjected to RFA alone and could potentially account for the
differences in our studies.
The difference between studies could also be attributed to random error because the sample
size of the Pouw et al3 study is approximately 1/20th of ours (254 fragments vs 5648
fragments). We believe that this is unlikely, given that both studies feature a large number of
biopsy samples. Biopsy technique may also account for the difference in subepithelial yield.
The Pouw et al study was conducted at a single site compared with the 19 sites in our study.
All sites in this study received instruction on biopsy technique and location, and biopsy
samples were taken from a deflated esophageal lumen. In short, although there are several
possible explanations, the reason for the marked difference in yield of subepithelial tissues
between the European and U.S. studies remains unclear.
Our study featured centralized histological interpretation by an expert GI pathologist, a
randomized sham control group that was concurrently recruited, highly standardized tissue
acquisition and processing, and more than 5000 individually graded biopsy samples.
However, several weaknesses of our study also deserve mention.
Although our biopsy technique, processing, and interpretation were standardized, our biopsy
samples were not individually mounted on filter paper or other substrate before fixation, nor
were they oriented in paraffin in a standardized manner. Therefore, it is quite likely that
some biopsy samples may have fragmented during processing. Such fragmenting might
actually bias the study to under-reporting of depth if surface squamous tissue fragmented
away from subepithelial structures. Although such rigorous methodology of specimen
handling might aid the pathologist in orientation, this is not a common clinical practice and
was not feasible, given the number of samples in the study. A small proportion (9%) of our
treatment population underwent limited EMR before randomization. As noted previously,
post-EMR tissue might be characteristically different from tissue that underwent RFA alone,
and it could potentially be more difficult to perform a biopsy of it. Given the limited number
of subjects who underwent EMR, the even distribution of post-EMR patients between the
RFA and sham arms, and the fact that EMRs were limited to areas with nodular disease, it is
unlikely that these interventions affected our findings to any substantial degree.
Additionally, all samples were interpreted regardless of quality. Although allowing some
samples to be labeled “inadequate for interpretation” could remove problematic fragments,
we attempted to capture the breadth of sample quality that one might see in routine
surveillance. Finally, the thickness of the epithelial layer was not directly measured. It is
possible that after ablation, neosquamous epithelium becomes thicker over time as it
regenerates and thus influences the probability of detecting SSIM. However, as detailed
previously, if this were true, we would have expected to see a higher subepithelial yield in
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the squamous biopsy samples from RFA patients compared with sham patients because
sham squamous epithelium underwent no regeneration.
In summary, the majority of biopsy samples obtained from patients after RFA treatment
contained subepithelium and were therefore adequate to evaluate for SSIM. However, a
higher proportion of columnar mucosal biopsy samples contained subepithelium compared
with neosquamous mucosal biopsy samples. After controlling for the type of epithelium that
underwent biopsy, biopsy samples from treated subjects were as likely to demonstrate
subepithelium as biopsy samples from the sham group. These findings suggest that
endoscopic esophageal biopsy samples after RFA are of adequate depth to assess for SSIM.
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A, Partial-thickness squamous epithelium. B, Full-thickness squamous epithelium. C,
Squamous mucosa with abundant underlying LP. D, Squamous mucosa with underlying
muscularis mucosae. E, Squamous mucosa with underlying muscle and small amount of
submucosa. F, Squamous mucosa with numerous LP papillae (arrows).
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Enrollment and 1-year follow-up.
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TABLE 1
Patient demographics and characteristics
RFA Sham
No. patients 78 35
Age, y, mean 66.6 ± 8.5 64.7 ± 8.5
Sex, no. (%)
 Female 11 (14) 3 (9)
 Male 67 (86) 32 (91)
Race, no. (%)
 White 73 (94) 35 (100)
 Black 2 (3) 0 (0)
 Latino 3 (4) 0 (0)
Body mass index, mean* 28.4 ± 4.9 31.1 ± 5.8
Length of Barrett's esophagus (cm), mean 5.0 ± 2.2 4.6 ± 2.4
High-grade dysplasia, no. (%) 38 (49) 16 (46)
Multifocal dysplasia, no. (%) 59 (76) 25 (71)
History of endoscopic mucosal resection, no. (%) 7 (9) 4 (11)
Mean values are reported as mean ± standard deviation.
RFA, Radiofrequency ablation.
*
P < .05 for the comparison of the radiofrequency-treated and sham groups based on 2-sample t test.
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